Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 1338
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
CASE REPORT
Year : 2016  |  Volume : 5  |  Issue : 4  |  Page : 315-319

Favorable response in “locally advanced stage” of adenocarcinoma lung to erlotinib: Quality of life and clinical and radiological outcome are satisfactory after 24 weeks


1 Department of Pulmonary Medicine, MIMSR Medical College, Latur, Maharashtra, India
2 Department of Pathology, Government Medical College, Latur, Maharashtra, India

Correspondence Address:
Shital Patil
Department of Pulmonary Medicine, MIMSR Medical College, Latur, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-0513.186103

Rights and Permissions

Lung cancer is one of the most common types of cancer and the leading cause of human cancer deaths worldwide. Adenocarcinoma is the most common histological type of lung cancer. Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) have been reported to exert a significant impact in the treatment of nonsmall cell lung cancer, particularly in patients harboring mutations in the EGFR gene. In this case report, 41 years male with “locally advanced stage” of lung cancer presented with shortness of breath on routine work and compromised quality of life, diagnosed to have malignant pleural effusion after pleural fluid cytology evaluation. We performed bronchoscopy guided transbronchial lung biopsy and confirmed to have adenocarcinoma lung after histopathology evaluation. We further analyzed thyroid transcription factor-1 and EGFR mutation study in histopathology sample and started “targeted therapy” with erlotinib. We documented excellent clinical and radiological response with complete resolution of pleural fluid and lung parenchymal lesion, and significant improvement in quality of life after 6 weeks of erlotinib. We used erlotinib as a “maintenance therapy” in adenocarcinoma lung for 24 weeks.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1251    
    Printed18    
    Emailed0    
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal